NOL Index Technology
AI-powered sensor platform that quantifies pain response
Platform · EmbeddedCompany source
Company profile
About Medasense Biometrics
Medasense Biometrics is a medical technology company transforming how pain is assessed and treated in clinical settings through breakthrough artificial intelligence technology. The company's core innovation is the NOL (Nociception Level) Index, an AI-powered platform that objectively quantifies pain response to optimize patient care and avoid overmedication. Their flagship product, the PMD-200™ monitor, is used in critical care and surgical settings to visualize pain response in real-time and personalize analgesic treatment. The technology addresses a major clinical challenge: pain affects hundreds of millions of people globally with annual costs exceeding $1 trillion. By eliminating guesswork in pain assessment, Medasense's NOL technology enables clinicians to make confident, data-driven decisions about analgesia management. Clinical studies have demonstrated significant impact on patient safety and outcomes, including a 33% reduction in reported postoperative pain. The company's pipeline includes NOLedge™, which applies AI capabilities for pain prediction, stratification, and prevention strategies. Medasense serves hospitals, surgical centers, and critical care facilities globally through an established distribution network, and provides comprehensive clinical education through the Medasense Academy training program for healthcare professionals and commercial partners.
Company description Medasense Biometrics official website
Primary marketRemote Patient Monitoring & Wearables
Commercial modelCommercial information available on request
Work at Medasense Biometrics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Bariatric surgery
- Colorectal surgery
- Critical care pain assessment
- Intraoperative pain management
- Orthognathic surgery
- Postoperative pain
- Spine surgery
- Thoracic surgery
Who it serves
- Anesthesiology Departments
- Critical Care Facilities
- Health Systems
- Hospitals
- Surgical Centers
Deployment & integration
Embedded · Other deployment with recorded integration context.
Geographic context
MarketsEurope · Global · Latin America · United States
Company sourceOfficial website
Company milestones
Platform expansion
Collaboration with Jefferson Health on spine surgery pain monitoring study; Grant awarded with Blink Device Company for advanced anesthesia monitoring system; Appointment of Peter Wehrly as Executive Chairman of the Board
Partnerships
Recorded partners
- Blink Device Company (advanced anesthesia monitoring system development grant)
- Global distribution partners
- Jefferson Health (spine surgery study collaboration)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
NOLedge™
Pipeline product applying AI for pain prediction and prevention
Platform · OtherCompany source
PMD-200™
AI-powered pain monitoring device for critical care settings
Device · EmbeddedCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Nociception level index as a tool of measuring pain objectively in patients with complex regional pain syndrome: a feasibility study.Frontiers in pain research (Lausanne, Switzerland) · Jan 1, 2025
Initial Validation of the NOL Nociception Level Index® Monitoring System in Black and Multiracial People.Medical devices (Auckland, N.Z.) · Jan 1, 2024
Generalizability of nociception level as a measure of intraoperative nociceptive stimulation: A retrospective analysis.Acta anaesthesiologica Scandinavica · Oct 1, 2023
Reduced postoperative pain in patients receiving nociception monitor guided analgesia during elective major abdominal surgery: a randomized, controlled trial.Journal of clinical monitoring and computing · Apr 1, 2023
Implementing capnography to help improve patient safety during procedural sedation: quality improvement in a high-volume gastroenterology department.European journal of gastroenterology & hepatology · Dec 1, 2021
Nociception monitor-guided opioid administration in radical retropubic prostatectomy. Manufacturer's response to Br J Anaesth 2020; 126: 516-24.British journal of anaesthesia · May 1, 2021
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
PMD-200DEN210022 · De Novo · Feb 17, 2023
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
33% reduction in reported postoperative pain
Clinical studies with NOL monitoring
Improved patient safety
Clinical evidence from multiple studies
Cost savings
Economic value through optimized analgesia management
Reduced overmedication
Personalized pain treatment approach
Clinical Study - Remifentanil-Propofol Anesthesia
Nociception-guided versus standard care during anesthesia procedures
33% reduction in reported postoperative pain
Jefferson Health
Collaboration on study of pain monitoring technology in spine surgery
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Peter Wehrly
Executive Chairman of the Board
06 · Company updates
Updates from Medasense Biometrics
Recent articles published on Medasense Biometrics's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Remote Patient Monitoring & Wearables
Companies providing AI-powered remote patient monitoring solutions, wearable health devices with AI analytics, continuous health tracking, or platforms that monitor patients outside clinical settings. Includes general wellness wearables with AI coaching, respiratory monitoring devices, and connected health platforms that aggregate and analyze physiological data from sensors.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.